Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | APOB | P04114 | 6/20 | 0.51 |
| ▸ | MTTP | P55157 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806887 | 0.90 | NAMPT (0.56) | NAMPTP2RY14MAPTAPOBMTTP | |
| SCHEMBL6698710 | 0.85 | MAPT (0.56) | NAMPTMAPTAPOBMTTPGAA | |
| SCHEMBL13216249 | 0.82 | TRPV1 (0.58) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL5153696 | 0.82 | APOB (0.52) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL785584 | 0.82 | MTTP (0.49) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL785583 | 0.82 | MTTP (0.49) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL786048 | 0.82 | MTTP (0.49) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL13329128 | 0.82 | MTTP (0.50) | MAPTAPOBMTTPGAASMN1; SMN2 | |
| SCHEMBL2297690 | 0.81 | P2RY14 (0.64) | NAMPTP2RY14MAPTJAK3PTK2 | |
| SCHEMBL28267041 | 0.80 | P2RY14 (0.61) | NAMPTP2RY14MAPTJAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | NAMPT 396/4885P2RY14 3711/4885MAPT 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.